Pharmaceutical Production Facilities: Design and Applications considers the concepts and constraints that have to be considered in the design of small, medium and large scale production plants. The layout, along with the flow of materials and personnel through facilities are considered with reference to ensuring compliance with current good manufac
The central purpose of this book is to impart knowledge, skills and practical - plementation methods for the planning and operation of adaptable production - cilities and factories. It addresses planning methods and procedures for various types of production facility up to and including entire factories, and is aimed at practicing factory planners and students alike. The book provides facts and demonstrates practical processes using case studies for the purposes of illustration, so that ultimately skills can be acquired that make independent practical implementation and app- cation possible. It is based on up-to-the-minute practical experience and univ- sally applicable knowledge of the planning and technological design of adaptable production facilities (manufacturing and assembly) and factories. In comparison to existing, thematically-similar reference books, what is in- vative about this manual is that it provides the impulse for a more flexible pl- ning approach for the efficient design of adaptable production facilities using - sponsive, unconventional planning and organizational solutions. The book aims to provide a way of integrating systematic and situation-driven planning methods in a meaningful way. Situation-driven planning is becoming increasingly important to production facilities in these fast-moving times of change, in particular in terms of resource and energy efficiency. Existing technical and organizational course of action in terms of resources (both human and technical) need to be selected for the specific case at hand, and changes (to workshops, products, processes and equ- ment) need to be managed.
Radioisotopes are used worldwide in a range of medical, industrial, research and academic applications. A large proportion of these radioisotopes are produced in particle accelerators, and the number of institutions that operate linear accelerators or cyclotrons and manufacture and distribute radiopharmaceuticals, for example, is significant and increasing. The production of radioisotopes using particle accelerators poses significant radiation hazards to workers, members of the public, and the environment when accelerators are operated without adequate radiation safety measures. This Safety Guide provides practical guidance for implementing radiation protection and safety measures in such facilities involved in the production and use of radioisotopes.
From 1980 to 1993, the domestic production of uranium declined from almost 44 million pounds U3O8 to about 3 million pounds. This retrenchment of the U.S. uranium industry resulted in the permanent closing of many uranium-producing facilities. Current low uranium prices, excess world supply, and low expectations for future uranium demand indicate that it is unlikely existing plants will be reopened. Because of this situation, these facilities eventually will have to be decommissioned. The Uranium Mill Tailings and Radiation Control Act of 1978 (UMTRCA) vests the U.S. Environmental Protection Agency (EPA) with overall responsibility for establishing environmental standards for decommissioning of uranium production facilities. UMTRCA also gave the U.S. Nuclear Regulatory Commission (NRC) the responsibility for licensing and regulating uranium production and related activities, including decommissioning. Because there are many issues associated with decommissioning-environmental, political, and financial-this report will concentrate on the answers to three questions: (1) What is required? (2) How is the process implemented? (3) What are the costs? Regulatory control is exercised principally through the NRC licensing process. Before receiving a license to construct and operate an uranium producing facility, the applicant is required to present a decommissioning plan to the NRC. Once the plan is approved, the licensee must post a surety to guarantee that funds will be available to execute the plan and reclaim the site. This report by the Energy Information Administration (EIA) represents the most comprehensive study on this topic by analyzing data on 33 (out of 43) uranium production facilities located in Colorado, Nebraska, New Mexico, South Dakota, Texas, Utah, and Washington.
